5. Detailed adverse events in people with prodromal Alzheimer's Disease (24‐month follow‐up, AST analysis).
| Outcome | intervention group n = 152 | control group n = 157 | RR and 95% CI |
| Specific safety: most common serious adverse events | |||
| Myocardial infarction | 0 | 2 | 0.21 (0.01 to 4.27) |
| Fall | 2 | 1 | 2.07 (0.19 to 22.55) |
| Intervertebral disc protrusion | 0 | 2 | 0.21 (0.01 to 4.27) |
| Osteoarthritis | 0 | 3 | 0.15 (0.01 to 2.83) |
| Syncope | 3 | 0 | 7.23 (0.38 to 138.78) |
| (Major) depression | 1 | 3 | 0.34 (0.04 to 3.27) |
| Cardiac operation | 0 | 2 | 0.21 (0.01 to 4.27) |
| Hospitalisation | 2 | 0 | 5.16 (0.25 to 106.68) |
| Circulatory collapse | 2 | 0 | 5.16 (0.25 to 106.68) |
| Specific safety: most common adverse events | |||
| Vertigo | 6 | 12 | 0.52 (0.20 to 1.34) |
| Diarrhoea | 7 | 14 | 0.52 (0.21 to 1.24) |
| Cystitis | 4 | 9 | 0.46 (0.14 to 1.46) |
| Nasopharyngitis | 7 | 16 | 0.45 (0.19 to 1.07) |
| Respiratory tract infection | 7 | 9 | 0.80 (0.31 to 2.10) |
| Urinary tract infection | 7 | 9 | 0.80 (0.31 to 2.10) |
| Fall | 11 | 8 | 1.42 (0.59 to 3.43) |
| Arthralgia | 4 | 9 | 0.46 (0.14 to 1.46) |
| Back pain | 10 | 5 | 2.07 (0.72 to 5.90) |
| Headache | 9 | 12 | 0.77 (0.34 to 1.79) |
| Cough | 2 | 10 | 0.21 (0.05 to 0.93) |